Longeveron (LGVN) Enterprise Value (2021 - 2026)
Longeveron's (LGVN) quarterly Enterprise Value came in at -$15.8 million in Q1 2026, down 9.99% year-on-year from -$17.5 million in Q1 2025, and down 238.08% quarter-over-quarter from -$4.7 million in Q4 2025.
Longeveron (LGVN) Enterprise Value (2021 - 2026) Analysis & Trends
Longeveron's Enterprise Value history runs 6 years deep, the most recent figure standing at -$15.8 million for Q1 2026.
- On a quarterly basis, Enterprise Value fell 9.99% year-over-year to -$15.8 million in Q1 2026; TTM through Mar 2026 was -$15.8 million, a 9.99% decrease from a year earlier, with the FY2025 full-year figure at -$4.7 million, up 75.76% from the prior year.
- Enterprise Value eased to -$15.8 million in Q1 2026 per LGVN's latest filing, from -$4.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$2.3 million in Q1 2024 and bottomed at -$22.8 million in Q3 2024.
- The 5-year median for Enterprise Value is -$9.8 million (2025), against an average of -$10.8 million.
- Biggest YoY gain for Enterprise Value was 75.76% in 2025; the steepest drop was 525.36% in 2025.
- Year by year, Enterprise Value stood at -$19.7 million in 2022, then surged by 72.73% to -$5.4 million in 2023, then tumbled by 258.74% to -$19.2 million in 2024, then soared by 75.76% to -$4.7 million in 2025, then sank by 238.08% to -$15.8 million in 2026.
- Per Business Quant, the three latest LGVN Enterprise Value figures stand at -$15.8 million (Q1 2026), -$4.7 million (Q4 2025), and -$9.2 million (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Longeveron | 3.97 Mn | -11.79 Mn | 264,000.00 | -15.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.76 Mn |
| Dec 31, 2025 | -4.66 Mn |
| Sep 30, 2025 | -9.24 Mn |
| Jun 30, 2025 | -10.30 Mn |
| Mar 31, 2025 | -14.33 Mn |
| Dec 31, 2024 | -19.23 Mn |
| Sep 30, 2024 | -22.78 Mn |
| Jun 30, 2024 | -12.40 Mn |
| Mar 31, 2024 | -2.29 Mn |
| Dec 31, 2023 | -5.36 Mn |
| Sep 30, 2023 | -3.93 Mn |
| Jun 30, 2023 | -8.66 Mn |
| Mar 31, 2023 | -2.30 Mn |
| Dec 31, 2022 | -19.66 Mn |
| Dec 31, 2021 | -35.04 Mn |